CDMOs Have Integrated Packaging Into Early Drug Development
Contract manufacturers are investing billions in global infrastructure to accelerate pharmaceutical production timelines.
Updated on Oct. 2, 2026 in Consumer Goods
Live Poll
Do you trust companies that bundle multiple services into one provider to deliver better overall outcomes?
Contract development and manufacturing organizations (CDMOs) have increasingly integrated packaging development into the earliest stages of pharmaceutical production. This shift aims to reduce project complexity and align packaging requirements with regulatory and quality standards.
Why it matters
Pharmaceutical firms are adopting hybrid models to improve accountability and execution speed. By embedding packaging experts early in the development lifecycle, companies can better manage human factors and quality mandates before reaching commercial scale.
PCI Pharma Services has committed over $1 billion in infrastructure investments, including a $100 million expansion in San Diego. Meanwhile, Vetter is constructing a 160,000-square-foot clinical manufacturing facility in Des Plaines, IL.
The players
PCI Pharma Services
This company provides integrated pharmaceutical supply chain solutions including manufacturing and packaging services.
Vetter
Vetter is a global provider of contract development and manufacturing services for injectable drugs.
Thermo Fisher Scientific
Thermo Fisher is a global supplier of scientific instrumentation, reagents, and contract development services.
Allure Beauty Concepts
This firm operates specialized manufacturing sites that meet FDA and cGMP compliance standards.
The details
Companies are now utilizing integrated pathways that combine formulation, scale-up, and manufacturing with specialized packaging. Major industry players, including Thermo Fisher Scientific and Allure Beauty Concepts, are aggressively expanding their physical capacity through both site acquisitions and new facility construction.
Timeline
Thermo Fisher acquired a sterile manufacturing site in Ridgefield, NJ, in 2025.
The high-speed isolator line in San Diego is scheduled to be operational in 2028.
The clinical manufacturing facility in Des Plaines, IL, is scheduled to become operational in 2029.
Market Landscape
This move toward integrated packaging reflects a broader trend of CDMO consolidation where providers capture more of the value chain. This strategy allows firms to compete more effectively against rivals by offering a streamlined, one-stop-shop for drug developers.
Consumers may eventually see faster access to new medications as drug development cycles shorten due to better integrated manufacturing. While direct pricing impacts remain unclear, the improvement in production accountability is designed to reduce the risk of product delays.
The takeaway
The integration of packaging into the early stages of drug development marks a fundamental shift toward greater operational efficiency in the pharmaceutical industry. By prioritizing these capabilities now, manufacturers aim to minimize costly adjustments that traditionally occur during the final stages of commercialization.
Further reading
Learn more about the latest trends in the Consumer Goods sector.
Source note: This article includes information reported by PlasticsToday.
Live Poll
Do you trust companies that bundle multiple services into one provider to deliver better overall outcomes?
